The treatment of type 2 diabetes involves balancing three major risks: hypoglycemia (particularly nocturnal episodes in elderly patients), glycemic fluctuations throughout the day, and medication-associated weight gain.
Even when HbA1c targets are achieved, blood glucose can fluctuate dramatically due to elevated basal levels and loss of postprandial control.
Individualized HbA1c Targets
For most non-pregnant adults, the ADA recommends an HbA1c below 7%, with more stringent goals of less than 6.5% considered when achievable without increasing hypoglycemia risk.
Less stringent targets (7-8% or even up to 8%) are appropriate for patients with limited life expectancy, history of severe hypoglycemia, advanced complications, or extensive comorbidities.
Blood glucose monitoring is important for achieving glycemic goals for many individuals with type two diabetes, and is it especially useful in patients taking insulin.
Treatment Progression
Treatment follows a stepwise approach starting with lifestyle modifications (150 minutes weekly of moderate exercise, 5-10% weight loss) plus metformin as first-line therapy.
If HbA1c goals aren’t met within approximately three months, therapy is intensified by adding a second agent, then triple therapy if needed.
Modern guidelines increasingly emphasize comorbidity-driven selection.
SGLT2 inhibitors are prioritized for patients with heart failure or chronic kidney disease, while GLP-1 receptor agonists are preferred for those at increased stroke risk or needing weight loss.
Both classes reduce cardiovascular events and have low hypoglycemia risk.
Notably, SGLT2 inhibitors show greater cardioprotection in older patients, while GLP-1 agonists are more cardioprotective in younger individuals.
Metformin should generally be continued even after insulin initiation unless contraindicated.
When newer agents (SGLT2 inhibitors or GLP-1 agonists) achieve adequate control, sulfonylureas and long-acting insulins should be reduced or discontinued due to their higher hypoglycemia risk and inferior mortality outcomes.
For patients on metformin plus an SGLT2 inhibitor or GLP-1 agonist, self-monitoring of blood glucose may be unnecessary.
While females have lower absolute risk of type 2 diabetes and cardiovascular disease compared to males, diabetes confers a greater relative increase in cardiovascular risk in women than in men.
Beyond glycemic control, management must address blood pressure, lipid levels, often with statins, smoking cessation, and albuminuria.
When these factors are well-controlled, patients with type 2 diabetes can achieve cardiovascular risk similar to those without diabetes.
However, glycemic lowering alone does not reduce macrovascular disease, the leading cause of death in type 2 diabetes.